欢迎来到天天文库
浏览记录
ID:52946216
大小:553.37 KB
页数:3页
时间:2020-04-02
《联合治疗血液透析并发症的临床效果_李新华.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、华南国防医学杂志2014年1月28日第28卷第1期MilMedJSChin,Vol.28,No.1,January28,2014·25·左卡尼汀、重组人促红细胞生长素及铁剂联合治疗血液透析并发症的临床效果李新华,杨红荣,刘丹,叶艳,李勇【摘要】目的探讨左卡尼汀、重组人促红细胞生长素及铁剂联合治疗血液透析并发症的临床效果。方法将作者医院2011-02/2012-02月60例血液透析并发症患者按照随机数字法分为对照组与观察组,均给予重组人促红细胞生长素+铁剂,观察组另外还给予左卡尼汀,观察两组的临床治疗效果。结果观察组治疗后的胸闷、心悸、乏力、低血压症状均完全消失(P<0.05),且心肌收
2、缩加强;对照组治疗后的胸闷、心悸、乏力、低血压症、心律失常较治疗前改善不明显(P>0.05)。两组治疗后临床症状与体征改善情况比较具有明显差异(P<0.05)。两组治疗后血红蛋白、红细胞比容、血清铁蛋白和转铁蛋白饱和度较治疗前有明显改善,且治疗后两组差异有统计学意义(P<0.05)。结论临床中对于血液透析并发症患者给予左卡尼汀、重组人促红细胞生长素及铁剂联合治疗效果显著,能够有效的改善患者的不良反应,并改善其心功能,值得临床中应用。【关键词】血液透析;并发症;左卡尼汀;重组人促红细胞生长素;铁剂;临床疗效【中图分类号】R586【文献标识码】Adoi:10.3969/j.issn.100
3、9-2595.2014.01.008ClinicalEffectofLevocarnitineRecombinantHumanErythropoietinandIronCombinationTherapyinTreatmentofHemodi-alysisComplicationsLIXin-hua,YANGHong-rong,LIUDan,YEYan,LIYong.DepartmentofNephorology,TheAffiliatedShiyanTaiheHospital,HubeiMedicalCollege,ShiyanHubei442000,China【Abstract】O
4、bjectiveTostudytheefficacyoflevocarnitine,recombinanthumanerythropoietinandironcombina-tiontherapyinthetreatmentofhemodialysiscomplications.MethodsSixtycaseswithcomplicationofhemodialysisinourhospitalfromFebruary2011toFebruary2012wererandomlydividedintocontrolgroupandobservationgroup.Thecontrolg
5、roupwastreatedwithrecombinanthumanerythropoietinandiron.Theobservationgroupwastreatedadditional-lywithlevocarnitine.Theefficacyofthetwogroupswasobserved.ResultsThesymptomsincludingtightnessinthechest,palpitation,weakness,lowbloodpressureintheobservationgroupaftertreatmentcompletelydisappeared(P<
6、0.05),andmyocardialcontractionwasstrengthened.Thesesymptomsandcardiacarrhythmiawerenotsignificantlyim-provedinthecontrolgroupaftertreatment(P>0.05).Theimprovementoftheclinicalsymptomsandsignsaftertreat-mentweresignificantdifferentbetweentwogroups(P<0.05).Thehemoglobin,hematocrit,serumferritinand
7、transfer-rinsaturationofthetwogroupsweresignificantlyimprovedthanthosebeforetreatmentandsignificantlydifferentbe-tweentwogroupsaftertreatment(P<0.05).ConclusionInclinicalpractice,levocarnitine,recombinanthumaneryth-ropoietin
此文档下载收益归作者所有